Paul Devlin played a "significant role" throughout the group's fundraise used for the acquisition of CellRight Technologies
() said on Friday that chief financial officer Paul Devlin will step down and the medical device company has started the process to appoint a successor.
Steve Couldwell, who was named as chief executive in November, said: "Paul played a significant role throughout the fundraise and acquisition process, we wish him every success in the future."
In August, Tissue raised £40mln from investors, of which £25mln was used to complete the “transformational” acquisition of CellRight Technologies.
Alongside the announcement of Devlin’s departure, the company said it has issued and allotted 552,337 ordinary shares of 0.5p each following the exercise of options.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE